Triple-negative breast cancer (TNBC) is negative for the three current treatment-predictive markers (estrogen receptor, ER, progesterone receptor, PR, and ERBB2/HER2 gene amplification) and constitutes ~10–20% of patients with primary disease1,2. Here, ESR1 is linked to triple-negative breast carcinoma.